Dakota Wealth Management lessened its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 41.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,199 shares of the company’s stock after selling 63,847 shares during the period. Johnson & Johnson accounts for 0.9% of Dakota Wealth Management’s portfolio, making the stock its 20th largest holding. Dakota Wealth Management’s holdings in Johnson & Johnson were worth $14,136,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC raised its position in shares of Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after acquiring an additional 54,326,454 shares during the last quarter. Norges Bank bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $4,609,399,000. Morgan Stanley raised its position in shares of Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after acquiring an additional 4,521,062 shares during the last quarter. Nordwand Advisors LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at $785,273,000. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Johnson & Johnson by 15.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after buying an additional 3,849,148 shares in the last quarter. Institutional investors own 67.57% of the company’s stock.
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $164.10 on Friday. The stock has a market capitalization of $426.45 billion, a price-to-earnings ratio of 34.33, a PEG ratio of 2.79 and a beta of 0.54. The business has a 50-day moving average of $160.73 and a 200-day moving average of $163.23. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $181.04.
Johnson & Johnson Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd were issued a dividend of $1.19 per share. The ex-dividend date was Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a yield of 2.90%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio (DPR) is presently 99.58%.
Analysts Set New Price Targets
JNJ has been the subject of a number of recent analyst reports. Citigroup initiated coverage on shares of Johnson & Johnson in a research report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price objective for the company. UBS Group initiated coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price objective for the company. Atlantic Securities lowered their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research report on Wednesday, April 19th. Raymond James reduced their target price on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research note on Wednesday, April 19th. Finally, TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, May 19th. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $171.57.
Insiders Place Their Bets
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.20% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Is it Time To Ring The Register On Paychex?
- Micron Technology: A Reversal Is Imminent
- Can Topgolf Callaway Brands Crawl Out of the Bunker and Rally?
- McCormick Rebound Imminent: Executive Transition Complete
- 3 Reasons Boston Beer Stock Could Finally Hop Higher
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
